EV-301 investigator discusses enfortumab vedotin: "Significant survival advantage" vs chemotherapy was observed.

THERAPEUTIC use of monoclonal antibodies; THERAPEUTIC use of antineoplastic agents; BLADDER tumors; METASTASIS; ANTINEOPLASTIC agents; CELL adhesion molecules; PHARMACODYNAMICS

An interview with Barts Cancer Centre director Thomas Powles is presented. He describes the outcomes for patients with metastatic urothelial carcinoma who show improvement after platinum-containing chemotherapy. The evaluation of the use of enfortumab vedotin as an antibody-drug conjugate targeting Nectin-4 is discussed. Particular focus is also given to the toxicity profile of enfortumab vedotin as observed during the EV-301 study.